MEDINOL LTD.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 1992-12-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.medinol.com
Clinical Trials
17
Active:1
Completed:13
Trial Phases
3 Phases
Phase 2:1
Phase 4:1
Not Applicable:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Not Applicable
10 (83.3%)Phase 2
1 (8.3%)Phase 4
1 (8.3%)First in Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease And/or Proximal Popliteal Artery Disease
Not Applicable
Recruiting
- Conditions
- Popliteal Artery StenosisSuperficial Femoral Artery Stenosis
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06410313
- Locations
- 🇺🇸
Piedmont Healthcare, Inc., Atlanta, Georgia, United States
🇺🇸Columbia University Medical Center/ NewYork Presbyterian Hospital or CUMC/NYPH, New York, New York, United States
🇺🇸St Francis Hospital Heart Center, Roslyn, New York, United States
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Not Applicable
Not yet recruiting
- Conditions
- Coronary Artery DiseaseCoronary Stenosis
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06071702
IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Not Applicable
Active, not recruiting
- Conditions
- Coronary StenosisCoronary DiseaseNon-ST Elevated Myocardial InfarctionCardiovascular Diseases
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05364697
- Locations
- 🇧🇷
InCor, Sao Paulo, Brazil
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Rabin Medical Center, Petah tikva, Israel
BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
Completed
- Conditions
- Coronary StenosisMyocardial IschemiaCardiovascular DiseasesCoronary Disease
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04761939
- Locations
- 🇮🇱
Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Hillel Yafe Medical Center, Hadera, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
Completed
- Conditions
- Coronary Stenosis
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Medinol Ltd.
- Target Recruit Count
- 319
- Registration Number
- NCT03877848
- Locations
- 🇮🇱
Medinol LTD, Tel Aviv, Israel
- Prev
- 1
- 2
- 3
- Next
News
No news found